Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Non-Insulin Therapies For Diabetes Global Market Report 2025
Download Free Sample Buy Now
Global Non-Insulin Therapies For Diabetes Market Report 2025

Report Price : $4490.00

Pages : 175

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF
Purchase This Report

Non-Insulin Therapies For Diabetes Global Market Report 2025

By Drug Class (Biguanides, Sulfonylureas, Thiazolidinedione’s, Alpha-Glucosidase Inhibitors, Dipeptidyl peptidase-4 (DPP-, Inhibitors, Glucagon-like peptide-1 (GLP-– Analogs, Sodium-glucose co-transporter-2 (SGLT, Inhibitors), By Route Of Administration (Oral, Intramuscular), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), By Application (Monitoring, Diagnosis, Treatment, Other Applications) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Non-Insulin Therapies For Diabetes Market Overview

• Non-Insulin Therapies For Diabetes market size has reached to $19.98 billion in 2024

• Expected to grow to $26.98 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%

• Growth Driver: Role of Non-Insulin Therapies in Addressing the Global Diabetes Epidemic

• Market Trend: Advancements in Personalized Diabetes Management Systems

• North America was the largest region in 2024.

What Is Covered Under Non-Insulin Therapies For Diabetes Market?

Non-insulin therapies for diabetes refer to medications and treatments used to manage blood sugar levels in diabetic patients without the use of insulin injections. They are essential for regulating blood sugar levels in patients, who either do not need or prefer insulin injections.

The main classes of drugs in non-insulin therapies for diabetes market are biguanides, sulfonylureas, thiazolidinedione’s, alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) analogs, and sodium-glucose co-transporter-2 (SGLT2) inhibitors. Biguanides are oral hypoglycemic agents that treat type 2 diabetes by reducing liver glucose production and enhancing insulin sensitivity. These medications are available for administration via oral and intramuscular routes and are distributed through various channels, including retail pharmacies, hospital pharmacies, and online pharmacies. They are used for Monitoring, diagnosis, treatment, and others.

Non-Insulin Therapies For Diabetes Market Size and growth rate 2025 to 2029: Graph

What Is The Non-Insulin Therapies For Diabetes Market Size 2025 And Growth Rate?

The non-insulin therapies for diabetes market size has grown strongly in recent years. It will grow from $19.98 billion in 2024 to $21.21 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to increasing diabetes prevalence, increasing awareness of diabetes management, rise in healthcare expenditure, shift in lifestyle changes leading to higher incidence rates, surge in diagnosis, increasing government initiatives for diabetes care, and increasing investment in pharmaceutical R&D.

What Is The Non-Insulin Therapies For Diabetes Market Growth Forecast?

The non-insulin therapies for diabetes market size is expected to see strong growth in the next few years. It will grow to $26.98 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to rising diabetes prevalence, increasing awareness of diabetes management, growing adoption of combination therapies, expanding geriatric population, increasing healthcare expenditure, expansion of telemedicine, and growing preference for oral medications. Major trends in the forecast period include advancements in oral and injectable medications, advancements in drug delivery systems, advancements in oral peptide delivery, adoption of telemedicine and digital health solutions, and advancements in combination therapies.

The forecast of 6.2% growth over the next five years reflects a modest reduction of 0.6% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of Glucagon-Like Peptide-1 receptor agonists GLP-1 receptor agonists and Sodium-Glucose cotransporter 2 inhibitors SGLT2 inhibitors sourced from Denmark and India, thereby limiting diabetes management options and elevating endocrinology expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The Non-Insulin Therapies For Diabetes Market Segmented?

1) By Drug Class: Biguanides, Sulfonylureas, Thiazolidinedione’s, Alpha-Glucosidase Inhibitors, Dipeptidyl peptidase-4 (DPP-4) Inhibitors, Glucagon-like peptide-1 (GLP-1) Analogs, Sodium-glucose co-transporter-2 (SGLT2) Inhibitors

2) By Route Of Administration: Oral, Intramuscular

3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Online Pharmacy

4) By Application: Monitoring, Diagnosis, Treatment, Other Applications

Subsegments:

1) By Biguanides: Metformin, Combination Of Metformin With Other Drugs

2) By Sulfonylureas: Glimepiride, Glipizide, Glyburide

3) By Thiazolidinediones: Pioglitazone, Rosiglitazone

4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol

5) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin

6) By Glucagon-Like Peptide-1 (GLP-1) Analogs: Exenatide, Liraglutide, Dulaglutide, Semaglutide

7) By Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin

What Is Driving The Non-Insulin Therapies For Diabetes Market? Role of Non-Insulin Therapies in Addressing the Global Diabetes Epidemic

The increase in the prevalence of diabetes is expected to propel the growth of non-insulin therapies for the diabetes market going forward. Diabetes is a chronic medical condition characterized by high blood glucose (sugar) levels. It occurs when the body cannot produce enough insulin or properly use the insulin IT makes. The cases of diabetes is growing due to sedentary lifestyles, unhealthy diets, genetic predisposition, aging populations, obesity, ethnicity, lack of awareness, limited access to healthcare, and environmental factors. Non-insulin therapies for diabetes help treat the condition by improving insulin sensitivity, reducing glucose production in the liver, increasing glucose uptake in muscle cells, and enhancing overall glycemic control. For instance, in April 2023, according to a report published by The British Diabetic Association, a UK-based diabetes charity 4.3 million individuals in the UK were diagnosed with diabetes. Registration data for 2021-22 shows an increase of 148,951 cases compared to 2020-21. Additionally, over 2.4 million people in the UK are at high risk of developing type 2 diabetes. Therefore the increase in the prevalence of diabetes is driving the growth of non-insulin therapies for the diabetes market.

Who Are The Major Players In The Global Non-Insulin Therapies For Diabetes Market?

Major companies operating in the non-insulin therapies for diabetes market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi, The Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Les Servier Laboratories, Sumitomo Dainippon Pharma Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Uni-Bio Science Group Ltd., Intarcia Therapeutics, Janssen Pharmaceuticals, Boan Biotech, SatRx LLC

What Are The Key Trends Of The Global Non-Insulin Therapies For Diabetes Market? Advancements in Personalized Diabetes Management Systems

Major companies operating in the non-insulin therapies for diabetes market are developing personalized diabetes management systems to enhance patient outcomes through real-time monitoring, data analytics, and customized treatment plans. A customized diabetes management system adapts treatment and monitoring based on each patient's unique needs, leveraging real-time data and analytics to enhance care and results. For instance, in November 2022, Eli Lilly and Company, a US-based pharmaceutical company, launched the Tempo personalized diabetes management platform. The Tempo platform includes three main elements, such as the Tempo Smart Button, the TempoSmart app, and the prefilled insulin pen, the Tempo Pen. These components collaborate to provide tailored guidance for adults with diabetes. The technology is designed to assist adults with type 1 or type 2 diabetes and their healthcare providers in making informed, data-driven treatment decisions using Lilly insulins.

Need data on a specific region in this market?
Request Regional Data

What Are Latest Mergers And Acquisitions In The Non-Insulin Therapies For Diabetes Market? Eli Lilly Acquires Sigilon Therapeutics to Advance Encapsulated Cell Therapies for Type 1 Diabetes Treatment

In August 2023, Eli Lilly and Company, a US-based pharmaceutical company, acquired Sigilon Therapeutics Inc. for $309.6 million. This acquisition enables Lilly to advance its research and development of encapsulated cell therapies, such as SIG-002, for treating type 1 diabetes. The aim is to offer improved solutions that relieve individuals with type 1 diabetes from continuous disease management. Sigilon Therapeutics Inc. is a US-based biopharmaceutical company developing encapsulated cell therapies for treating type 1 diabetes.

What Is The Regional Outlook For The Global Non-Insulin Therapies For Diabetes Market?

North America was the largest region in the non-insulin therapies for diabetes market in 2024. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Non-Insulin Therapies For Diabetes Market?

The non-insulin therapies for diabetes market consist of sales of glucose meters, continuous glucose monitors (CGMs), insulin pumps, smart insulin pens, oral medications such as metformin and sulfonylureas, and injectable medications such as glp-1 receptor agonists. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Non-Insulin Therapies For Diabetes Industry?

The non-insulin therapies for diabetes market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the non-insulin therapies for diabetes industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Non-Insulin Therapies For Diabetes Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $21.21 billion
Revenue Forecast In 2034 $26.98 billion
Growth Rate CAGR of 6.2% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Drug Class: Biguanides, Sulfonylureas, Thiazolidinedione’s, Alpha-Glucosidase Inhibitors, Dipeptidyl peptidase-4 (DPP-
4) Inhibitors, Glucagon-like peptide-1 (GLP-1) Analogs, Sodium-glucose co-transporter-2 (SGLT
2) Inhibitors
2) By Route Of Administration: Oral, Intramuscular
3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Online Pharmacy
4) By Application: Monitoring, Diagnosis, Treatment, Other Applications Subsegments: 1) By Biguanides: Metformin, Combination Of Metformin With Other Drugs
2) By Sulfonylureas: Glimepiride, Glipizide, Glyburide
3) By Thiazolidinediones: Pioglitazone, Rosiglitazone
4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol
5) By Dipeptidyl Peptidase-4 (DPP-
4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin 6) By Glucagon-Like Peptide-1 (GLP-1) Analogs: Exenatide, Liraglutide, Dulaglutide, Semaglutide 7) By Sodium-Glucose Co-Transporter-2 (SGLT
2) Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi, The Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Les Servier Laboratories, Sumitomo Dainippon Pharma Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Uni-Bio Science Group Ltd., Intarcia Therapeutics, Janssen Pharmaceuticals, Boan Biotech, SatRx LLC
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Non-Insulin Therapies For Diabetes Market Characteristics

3. Non-Insulin Therapies For Diabetes Market Trends And Strategies

4. Non-Insulin Therapies For Diabetes Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Non-Insulin Therapies For Diabetes Growth Analysis And Strategic Analysis Framework

5.1. Global Non-Insulin Therapies For Diabetes PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Non-Insulin Therapies For Diabetes Market Growth Rate Analysis

5.4. Global Non-Insulin Therapies For Diabetes Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Non-Insulin Therapies For Diabetes Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Non-Insulin Therapies For Diabetes Total Addressable Market (TAM)

6. Non-Insulin Therapies For Diabetes Market Segmentation

6.1. Global Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Biguanides

Sulfonylureas

Thiazolidinedione’s

Alpha-Glucosidase Inhibitors

Dipeptidyl peptidase-4 (DPP-4) Inhibitors

Glucagon-like peptide-1 (GLP-1) Analogs

Sodium-glucose co-transporter-2 (SGLT2) Inhibitors

6.2. Global Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oral

Intramuscular

6.3. Global Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Retail Pharmacy

Hospital Pharmacy

Online Pharmacy

6.4. Global Non-Insulin Therapies For Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Monitoring

Diagnosis

Treatment

Other Applications

6.5. Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Biguanides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Metformin

Combination Of Metformin With Other Drugs

6.6. Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Sulfonylureas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Glimepiride

Glipizide

Glyburide

6.7. Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Thiazolidinediones, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Pioglitazone

Rosiglitazone

6.8. Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Alpha-Glucosidase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Acarbose

Miglitol

6.9. Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Sitagliptin

Saxagliptin

Linagliptin

Alogliptin

6.10. Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Glucagon-Like Peptide-1 (GLP-1) Analogs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Exenatide

Liraglutide

Dulaglutide

Semaglutide

6.11. Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Canagliflozin

Dapagliflozin

Empagliflozin

7. Non-Insulin Therapies For Diabetes Market Regional And Country Analysis

7.1. Global Non-Insulin Therapies For Diabetes Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Non-Insulin Therapies For Diabetes Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Non-Insulin Therapies For Diabetes Market

8.1. Asia-Pacific Non-Insulin Therapies For Diabetes Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Non-Insulin Therapies For Diabetes Market

9.1. China Non-Insulin Therapies For Diabetes Market Overview

9.2. China Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Non-Insulin Therapies For Diabetes Market

10.1. India Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Non-Insulin Therapies For Diabetes Market

11.1. Japan Non-Insulin Therapies For Diabetes Market Overview

11.2. Japan Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Non-Insulin Therapies For Diabetes Market

12.1. Australia Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Non-Insulin Therapies For Diabetes Market

13.1. Indonesia Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Non-Insulin Therapies For Diabetes Market

14.1. South Korea Non-Insulin Therapies For Diabetes Market Overview

14.2. South Korea Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Non-Insulin Therapies For Diabetes Market

15.1. Western Europe Non-Insulin Therapies For Diabetes Market Overview

15.2. Western Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Non-Insulin Therapies For Diabetes Market

16.1. UK Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Non-Insulin Therapies For Diabetes Market

17.1. Germany Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Non-Insulin Therapies For Diabetes Market

18.1. France Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Non-Insulin Therapies For Diabetes Market

19.1. Italy Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Non-Insulin Therapies For Diabetes Market

20.1. Spain Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Non-Insulin Therapies For Diabetes Market

21.1. Eastern Europe Non-Insulin Therapies For Diabetes Market Overview

21.2. Eastern Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Non-Insulin Therapies For Diabetes Market

22.1. Russia Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Non-Insulin Therapies For Diabetes Market

23.1. North America Non-Insulin Therapies For Diabetes Market Overview

23.2. North America Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Non-Insulin Therapies For Diabetes Market

24.1. USA Non-Insulin Therapies For Diabetes Market Overview

24.2. USA Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Non-Insulin Therapies For Diabetes Market

25.1. Canada Non-Insulin Therapies For Diabetes Market Overview

25.2. Canada Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Non-Insulin Therapies For Diabetes Market

26.1. South America Non-Insulin Therapies For Diabetes Market Overview

26.2. South America Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Non-Insulin Therapies For Diabetes Market

27.1. Brazil Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Non-Insulin Therapies For Diabetes Market

28.1. Middle East Non-Insulin Therapies For Diabetes Market Overview

28.2. Middle East Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Non-Insulin Therapies For Diabetes Market

29.1. Africa Non-Insulin Therapies For Diabetes Market Overview

29.2. Africa Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Non-Insulin Therapies For Diabetes Market Competitive Landscape And Company Profiles

30.1. Non-Insulin Therapies For Diabetes Market Competitive Landscape

30.2. Non-Insulin Therapies For Diabetes Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Sanofi Overview, Products and Services, Strategy and Financial Analysis

30.2.5. The Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Non-Insulin Therapies For Diabetes Market Other Major And Innovative Companies

31.1. AstraZeneca plc

31.2. Novartis AG

31.3. GSK plc

31.4. Takeda Pharmaceutical Company Limited

31.5. Eli Lilly and Company

31.6. Novo Nordisk A/S

31.7. Boehringer Ingelheim International GmbH

31.8. Les Servier Laboratories

31.9. Sumitomo Dainippon Pharma Co. Ltd.

31.10. Jiangsu Hansoh Pharmaceutical Group Co. Ltd.

31.11. Uni-Bio Science Group Ltd.

31.12. Intarcia Therapeutics

31.13. Janssen Pharmaceuticals

31.14. Boan Biotech

31.15. SatRx LLC

32. Global Non-Insulin Therapies For Diabetes Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Insulin Therapies For Diabetes Market

34. Recent Developments In The Non-Insulin Therapies For Diabetes Market

35. Non-Insulin Therapies For Diabetes Market High Potential Countries, Segments and Strategies

35.1 Non-Insulin Therapies For Diabetes Market In 2029 - Countries Offering Most New Opportunities

35.2 Non-Insulin Therapies For Diabetes Market In 2029 - Segments Offering Most New Opportunities

35.3 Non-Insulin Therapies For Diabetes Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Non-Insulin Therapies For Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Biguanides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Sulfonylureas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Thiazolidinediones, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Alpha-Glucosidase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Glucagon-Like Peptide-1 (GLP-1) Analogs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Global Non-Insulin Therapies For Diabetes Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Global Non-Insulin Therapies For Diabetes Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: Asia-Pacific, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: Asia-Pacific, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: Asia-Pacific, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: China, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: China, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: China, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: India, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: India, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: India, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Japan, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Japan, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Japan, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Australia, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Australia, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Australia, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Indonesia, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Indonesia, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Indonesia, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: South Korea, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: South Korea, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: South Korea, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: Western Europe, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: Western Europe, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Western Europe, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: UK, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: UK, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: UK, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: Germany, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: Germany, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Germany, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: France, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: France, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: France, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Italy, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Italy, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Italy, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Spain, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Spain, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Spain, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Eastern Europe, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Eastern Europe, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Eastern Europe, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: Russia, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: Russia, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: Russia, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: North America, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: North America, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: North America, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: USA, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: USA, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: USA, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: Canada, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: Canada, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Canada, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: South America, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: South America, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: South America, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Brazil, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Brazil, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Brazil, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Middle East, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Middle East, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Middle East, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Africa, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 80: Africa, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 81: Africa, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 82: Pfizer Inc. Financial Performance
  • Table 83: F. Hoffmann-La Roche AG Financial Performance
  • Table 84: Merck & Co. Inc. Financial Performance
  • Table 85: Sanofi Financial Performance
  • Table 86: The Bristol-Myers Squibb Company Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Non-Insulin Therapies For Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Biguanides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Sulfonylureas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Thiazolidinediones, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Alpha-Glucosidase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Glucagon-Like Peptide-1 (GLP-1) Analogs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Global Non-Insulin Therapies For Diabetes Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Global Non-Insulin Therapies For Diabetes Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: Asia-Pacific, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: Asia-Pacific, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: Asia-Pacific, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: China, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: China, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: China, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: India, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: India, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: India, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Japan, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Japan, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Japan, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Australia, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Australia, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Australia, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Indonesia, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Indonesia, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Indonesia, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: South Korea, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: South Korea, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: South Korea, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: Western Europe, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: Western Europe, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Western Europe, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: UK, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: UK, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: UK, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: Germany, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: Germany, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Germany, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: France, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: France, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: France, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Italy, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Italy, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Italy, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Spain, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Spain, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Spain, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Eastern Europe, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Eastern Europe, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Eastern Europe, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: Russia, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: Russia, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: Russia, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: North America, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: North America, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: North America, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: USA, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: USA, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: USA, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: Canada, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: Canada, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Canada, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: South America, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: South America, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: South America, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Brazil, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Brazil, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Brazil, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Middle East, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Middle East, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Middle East, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Africa, Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 80: Africa, Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 81: Africa, Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 82: Pfizer Inc. Financial Performance
  • Figure 83: F. Hoffmann-La Roche AG Financial Performance
  • Figure 84: Merck & Co. Inc. Financial Performance
  • Figure 85: Sanofi Financial Performance
  • Figure 86: The Bristol-Myers Squibb Company Financial Performance

Intestinal Fistula Treatment Market Overview 2025: Competitive Shifts, Forecast Models, and Emerging Opportunities

Read More About Intestinal Fistula Treatment Market Overview 2025: Competitive Shifts, Forecast Models, and Emerging Opportunities

Next-Gen Invasive Aspergillosis Therapeutics : Market Forecast, Transformation, and Long-Term Trajectories

Read More About Next-Gen Invasive Aspergillosis Therapeutics : Market Forecast, Transformation, and Long-Term Trajectories

Iron Deficiency Anemia Growth Trajectory: Key Forecasts and Strategic Insights

Read More About Iron Deficiency Anemia Growth Trajectory: Key Forecasts and Strategic Insights

Lewy Body Dementia Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

Read More About Lewy Body Dementia Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

Read More About A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

Read More About A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

A 2025 strategic report on market size, competitive landscape and expansion strategies in the medications for heart failure market.

Read More About A 2025 strategic report on market size, competitive landscape and expansion strategies in the medications for heart failure market.

Explore strategic insights and forecasts in the global virtual nutrition coach app market, offering competitive benchmarking and market growth trends.

Read More About Explore strategic insights and forecasts in the global virtual nutrition coach app market, offering competitive benchmarking and market growth trends.

Non-Insulin Therapies For Diabetes Global Market Report 2025 – By Drug Class (Biguanides, Sulfonylureas, Thiazolidinedione’s, Alpha-Glucosidase Inhibitors, Dipeptidyl peptidase-4 (DPP-, Inhibitors, Glucagon-like peptide-...

View Report

Non-injectable Insulin Global Market Report 2025 – By Type (Synthetic Insulin, Semi Synthetic Insulin), By Product (Pills, Sprays, Other Products), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Drug St...

View Report

OEM Insulation Global Market Report 2025 – By Insulation Type( Blankets, Rolls and Batts, Loose Fill, Other Insulation Types ), By Material Type( Mineral Wool, Polyurethane Foam (PUF), Flexible Elastomeric Foam (FEF), Ot...

View Report

Antidiabetics Global Market Report 2025 – By Drug Class (Insulin, GLP-1 Receptor Agonists, DPP- 4 Inhibitors, SGLT2 Inhibitors, Other Drug Classes,), By Diabetes Type (Type 1, Type 2), By Patient Population (Antidiabetic...

View Report

Antidiabetics Global Market Report 2025 – By Drug Class (Insulin, GLP-1 Receptor Agonists, DPP- 4 Inhibitors, SGLT2 Inhibitors, Other Drug Classes,), By Diabetes Type (Type 1, Type 2), By Patient Population (Antidiabetic...

View Report

Insuman Market Report 2025: Epidemiology, Pipeline Analysis, Market Size, Trends, And Global Forecast 2034 – By Patient Demographics (Pediatric Patients, Adult Patients, Elderly Patients), By Distribution Channel (Hospit...

View Report

Clinical Nutrition For Diabetes Care Global Market Report 2025 – By Product (Oral Nutrition, Parenteral Nutrition, Enteral Feeding Formulas), By Stage (Adult, Pediatric), By Sales Channel (Online, Retail, Institutional S...

View Report

Instant Tea Premix Global Market Report 2025 – By Product type (Cardamom Tea Premix, Ginger Tea Premix, Masala Tea Premix, Lemon Tea Premix, Plain Tea Premix, Lemon Grass Tea Premix), By Nature ( Organic Tea Premixes, Co...

View Report

Frequently Asked Questions

Non-insulin therapies for diabetes refer to medications and treatments used to manage blood sugar levels in diabetic patients without the use of insulin injections. They are essential for regulating blood sugar levels in patients, who either do not need or prefer insulin injections. For further insights on this market, request a sample here

The market major growth driver - Role of Non-Insulin Therapies in Addressing the Global Diabetes Epidemic. For further insights on this market, request a sample here

The non-insulin therapies for diabetes market size has grown strongly in recent years. It will grow from $19.98 billion in 2024 to $21.21 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to increasing diabetes prevalence, increasing awareness of diabetes management, rise in healthcare expenditure, shift in lifestyle changes leading to higher incidence rates, surge in diagnosis, increasing government initiatives for diabetes care, and increasing investment in pharmaceutical R&D. The non-insulin therapies for diabetes market size is expected to see strong growth in the next few years. It will grow to " $26.98 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to rising diabetes prevalence, increasing awareness of diabetes management, growing adoption of combination therapies, expanding geriatric population, increasing healthcare expenditure, expansion of telemedicine, and growing preference for oral medications. Major trends in the forecast period include advancements in oral and injectable medications, advancements in drug delivery systems, advancements in oral peptide delivery, adoption of telemedicine and digital health solutions, and advancements in combination therapies. For further insights on this market, request a sample here

The non-insulin therapies for diabetesmarket covered in this report is segmented –
1) By Drug Class: Biguanides; Sulfonylureas; Thiazolidinedione’s; Alpha-Glucosidase Inhibitors; Dipeptidyl peptidase-4 (DPP-4) Inhibitors; Glucagon-like peptide-1 (GLP-1) Analogs; Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
2) By Route Of Administration: Oral; Intramuscular
3) By Distribution Channel: Retail Pharmacy; Hospital Pharmacy; Online Pharmacy
4) By Application: Monitoring; Diagnosis; Treatment; Other Applications Subsegments:
1) By Biguanides: Metformin; Combination Of Metformin With Other Drugs
2) By Sulfonylureas: Glimepiride; Glipizide; Glyburide
3) By Thiazolidinediones: Pioglitazone; Rosiglitazone
4) By Alpha-Glucosidase Inhibitors: Acarbose; Miglitol
5) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin; Saxagliptin; Linagliptin; Alogliptin
6) By Glucagon-Like Peptide-1 (GLP-1) Analogs: Exenatide; Liraglutide; Dulaglutide; Semaglutide
7) By Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Canagliflozin; Dapagliflozin; Empagliflozin For further insights on this market, request a sample here

North America was the largest region in the non-insulin therapies for diabetes market in 2024. The regions covered in the non-insulin therapies for diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Major companies operating in the non-insulin therapies for diabetes market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi, The Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Les Servier Laboratories, Sumitomo Dainippon Pharma Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Uni-Bio Science Group Ltd., Intarcia Therapeutics, Janssen Pharmaceuticals, Boan Biotech, SatRx LLC. For further insights on this market, request a sample here.

Major trends in this market include Advancements in Personalized Diabetes Management Systems. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Non-Insulin Therapies For Diabetes Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top WhatsApp icon